• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Thu, May 22, 2025
Home » Trump administration impacts
Email
Tweet

Trump administration impacts

U.S. flag and White House podium

Key executive orders impacting operations at HHS health agencies

Biopharma execs weigh in on Trump tariffs

May 20

US HHS calls for MFN pricing commitments

US FDA rethinks COVID-19 boosters

May 15

US threat of most-favored-nation Rx pricing intensifies

May 14

Kennedy on HELP hot seat over budget, cuts and layoffs

May 13

Trump tariffs trigger US capital commitments

Korea pharma stocks rally; Celltrion welcomes US drug pricing

HHS asks for input on which regs to kill 

May 12

Pause on tariffs could boost med-tech earnings

Most-favored nation Rx pricing voluntary, for now

With trade agreement secured, US and UK await section 232 outcome

May 9

Investors unfazed by uncertainties around tariffs in med tech

Navigating the Trump tariffs, part two: Amgen, Biogen, others

May 8

US legal issues to track in pharma, biotech: Bio Korea 2025

May 7

Some unshod by Prasad nod as CBER change socks stocks

South Korea urges US to exempt pharma, allies from tariffs

US-funded gain-of-function research paused for stiffer oversight

May 6

EO offers US onshoring relief, FDA steps up foreign inspections

US states seek to undo HHS reorg, terminations

More stringency expected under new CBER head

May 5

Annual US 301 trade report has louder bark

Med-tech financings and guidance strong despite tariffs

May 2

Navigating the Trump tariffs: Biopharma execs weigh in

May 1

Klobuchar reiterates opposition to Trump tariffs

Filling the NIH funding gap to protect biopharma research

‘Everything is possible’: Pharmas navigate US market uncertainties

US HHS touts NIH-developed universal vaccine platform

April 30

Emerging markets presents opportunities for med tech

Senate hearing: US biomedical research at a crossroads

April 29

EO record among Day 100 Trump achievements

Advamed, Medtech Europe sound off on tariffs

April 28

100 days of uncertainty

April 25

Vaccine Integrity Project launched to tackle ‘unfortunate reality’

Med tech majors unfazed by tariffs

April 24

Boston Sci expects $200M tariff hit, still raises guidance

Clarification: Nonvoting industry adcom members still possible

US capital crunch pushes China biotechs to roundabout financings

April 23

US HHS axes women’s health research

Chinabio 2025: Europe-China pharma deals rise as US markets shut

Free trade zones not a simple workaround for tariffs

MDMA’s Leahey skeptical of reports of the demise of user fees

April 22

Roche follows other pharmas, committing $50B in US investment

Harvard fighting back with lawsuit against Trump administration

The BioWorld Insider podcast: Bracing for the impact of tariffs and grant cuts

  • Listen to the full podcast

April 21

Makary’s vision for slimmed-down US FDA somewhat reassuring

April 18

Budget woes ahead for US life sciences sector?

Ouch! Tariffs hit med tech harder than expected

April 17

Ouch! Tariffs hit med tech harder than expected

April 16

New Trump order zeroes in on drug prices

April 15

Impact of tariffs on supplies of semiconductor tough to calculate

April 14

Biopharma tariffs becoming more than a threat

April 11

Novartis boosting US manufacturing with $23B investment

April 10

Dems petition White House to ensure drug supply chains stay intact

Loss of experience at US FDA raises concerns as impact felt

April 9

Many US tariffs paused, pharma warned, EU put on notice

US-China trade war accelerates with biotech in the crosshairs

April 8

Experts cite deadly consequences of PEPFAR funding disruption

Markets lose ground as US Senate meets on Trump tariffs

Europe’s med-tech companies assessing implications of tariffs

Many med-tech company supply chains protected from tariffs

April 7

US court says no to NIH indirect rate cut, another suit filed

April 3

Impact of Trump tariffs on med tech proving difficult to anticipate

Biopharma exempt from US reciprocal tariffs, but not untouched

Tariffs pressure industry markets; uncertainty remains

Asia in firing line of Trump tariffs, but health care escapes largely unscathed

With ‘wholesale assault’ on research, bipartisan alarm at institutional failure

April 2

Trump cuts are 'gutting' research grants, 'destabilizing' science

US to impose ‘kind reciprocal’ tariffs on country-by-country basis

Kennedy called to Senate HELP hearing on HHS reorg

April 1

Where’s the ‘radical transparency’ Kennedy promised?

March 31

Marks’ departure intensifies regulatory uncertainty at US FDA

March 28

Australia looks to Asia as Trump administration threatens funding

Medidata CEO says digital therapeutics, drugs future of patient treatment

March 27

BIO survey points to ‘damaging impacts’ of Trump tariffs

HHS to cut staffing levels by 20,000 under efficiency initiative

March 26

Senate votes in Makary, Bhattacharya at FDA and NIH

March 25

Oz hits Wyden’s wall of skepticism in Senate CMS post hearing

March 24

CDC’s ACIP meeting rescheduled

March 21

EU seeking talented scientists amid US funding woes

March 19

Trump halves the FTC, firing Democratic commissioners

March 18

WHO looking to fill funding gap left by the US

March 14

Oz promises AI, innovation, lower drug prices if confirmed to lead CMS

Lost in trans-lation? Trump’s mouse charge doesn’t click

March 13

US CDC nomination withdrawn, reforms in the works

Just one more vote to go for FDA, NIH nominees

March 10  

As tariffs threaten US imports of APIs, companies reshore manufacturing

CDC briefing: Trump cuts disrupt disease surveillance, deplete talent

March 6  

US FDA nominee HELPed on the way to confirmation

March 5  

Bhattacharya shares his vision for US NIH

March 4  

Trump’s EOs keep coming as US agencies await new leadership

March 3  

NIH changes set industry up for workforce, ideas drought

Pallone, DeGette push back on FDA, other HHS dismissals

Feb, 25  

New admin toes the Biden line on Rx price negotiations

Feb. 24  

US lawmakers tell Kennedy: No more ‘indiscriminate’ terminations

Feb. 21  

Amid the chaos, focus on innovation, says Stifel’s Opler

Raft of FDA job cuts may slow med-tech approvals

Feb. 20  

Still waiting for the dust to settle at US FDA, throughout HHS

Feb. 19  

Pharmaceuticals named as tariff target, starting at 25%

Feb. 18  

Thousands of US HHS staff terminated in name of efficiency

AAAS 2025: Former NIH head Bertagnolli sounds warning on funding cuts

Feb. 14  

Trump administration an existential threat to science, warns AAAS chief

Feb. 13  

NIH funding plans threaten to derail ‘synergistic partnership’

Uncertainty builds amid Kennedy confirmation, Trump’s orders

Feb. 11

Court orders full stop to US NIH slashing of indirect rates

Infographic: Indirect costs of NIH grants

BIO CEO 2025: Navigating from policy to innovation to patients

BIO CEO 2025: Cognition CEO debates policy while advancing CT-1812

Feb. 10  

BIO CEO 2025: A ‘nice upswing’ in VC rounds, but uncertainty looms

Scientists warn NIH cost-cutting will impair research

Feb. 7  

Trump’s executive orders stacking up, along with challenges

Trump administration presents a mixed picture for med tech

Admin's actions toward science agencies 'not a measured reappraisal'

Mixed reactions from Asia on biotech implications of Trump 2.0

Speculations rise on US tariff impact on global pharma industry

Feb. 5

Doctors group sues US CDC, FDA, HHS over data takedown

Feb. 4

Kennedy advances toward confirmation as HHS secretary

China blacklists Illumina as part of US tariffs counter

Feb. 3

Trump’s new tariffs likely to hit med tech, but impact uncertain

One vote could keep RFK from getting out of committee

Jan. 29

Confirmation hearings begin for RFK as US HHS secretary

The science on vaccines and autism: no there there

FDA diversity-in-trials rules evaporate after ‘strident’ Trump EO

Jan. 23

Mum’s the word at US health agencies awaiting new leadership

Jan. 14

European Commission pushes back on Beijing’s med-tech policy

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 21, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 21, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 20, 2025
  • Scorpion Therapeutics patents p53 Y220 mutant activators

    BioWorld Science
    Work at Scorpion Therapeutics Inc. has led to the identification of cellular tumor antigen p53 (TP53) (Y220C mutant) activators reported to be useful for the...
  • Drug capsule and dollar sign

    Little bite from voluntary most-favored nation Rx pricing order

    BioWorld
    After a week of hype, the most-favored nation (MFN) drug pricing executive order (EO) U.S. President Donald Trump signed May 12 has a lot of bark but little bite,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe